SOCS6 and hepatocellular carcinoma: SSI-4 is under clinical development for hepatocellular carcinoma [3], and in our study demonstrated potent anti-leukemic effects in vitro and in vivo on roughly half of AML samples and models tested while showing no general or hematopoietic toxicities.